Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1613 1619 1655 1731
This examiner grants 12% of resolved cases
Sean James Steinke is an examiner in Tech Center 1700 and Art Unit 1613. The examiner has managed 16 resolved cases. The data shows an allowance rate of 12.5 percent, which indicates that a small minority of applications reach issuance. This rate suggests a very rigorous examination process where the vast majority of cases result in abandonment rather than a grant.
Despite the low base allowance rate, the interview lift is 42.9 percent. This high lift suggests that conducting an interview is a critical strategy, as it significantly increases the probability of an allowance. Practitioners can use this 42.9 percent lift to prioritize direct communication as a primary method for overcoming rejections. This impact is a defining characteristic of the examiner's historical data in Art Unit 1613.
The median time to allowance is 1200 days. This figure represents the typical duration for the prosecution cycle for successful applications. With 16 resolved cases as the basis for these metrics, the profile provides an indication of the timeline and success rates expected. These figures help practitioners manage expectations regarding the duration of the process in Tech Center 1700.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18115215 | CELLULOSE ACETATE PARTICLES, COSMETIC COMPOSITION, AND METHOD FOR PRODUCING CELLULOSE ACETATE PARTICLES | Non-Final OA | Daicel Corporation |
| 18684083 | POLYMERS AND NANOPARTICLES FOR INTRAMUSCULAR NUCLEIC ACID DELIVERY | Non-Final OA | The Johns Hopkins University |
| 18721830 | ACOUSTICALLY-RESPONSIVE BIOINKS FOR EXTRUSION-BASED 3D-BIOPRINTING | Non-Final OA | The Regents of the University of Michigan |
| 18720082 | A COMPOSITION COMPRISING POLYMERS | Non-Final OA | BASF SE |
| 18578350 | HERBICIDAL PHENYLURACILS | Non-Final OA | BASF SE |
| 18553452 | ADDITIVES FOR ENHANCING THE PESTICIDAL EFFECTIVENESS OF PESTICIDAL MICROORGANISMS | Non-Final OA | BASF SE |
| 17754214 | Stable Aqueous Compositions of Fertilizer and Agriculturally Active Compound | Final Rejection | BASF SE |
| 18577406 | Herbicidal Compositions | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 17792611 | MICROEMULSIONS WITH DICAMBA SALTS HAVING IMPROVED PROPERTIES | Final Rejection | MONSANTO TECHNOLOGY LLC |
| 18018220 | ARTIFICIAL PLACENTA VACCINE FOR ORGAN TRANSPLANTATION | Final Rejection | Arizona Board of Regents on Behalf of Arizona State University |
| 18069796 | ENCAPSULATION OF BIOACTIVE INGREDIENTS BY MULTIPLEX EMULSION | Final Rejection | The Board of Regents of the University of Texas System |
| 17625955 | METHOD FOR LOADING OF MICROORGANISMS ON MULTIPHASE BIOMATERIALS | Non-Final OA | Evonik Operations GmbH |
| 18706694 | POLYHYDROXYALKANOATE COPOLYMER BEARING AN ACETOACETATE GROUP, COMPOSITION CONTAINING SAME AND COSMETIC USE THEREOF | Non-Final OA | L'OREAL |
| 18518827 | COMPOSITIONS AND METHODS FOR TREATING KERATIN SUBSTRATES | Non-Final OA | L'Oreal |
| 18554855 | SOLID ANHYDROUS COMPOSITION FOR CARING FOR AND/OR MAKING UP KERATIN MATERIALS | Final Rejection | L'OREAL |
| 18015446 | AEROSOL PRODUCT | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18032856 | Opacifier Compositions | Non-Final OA | Clariant International Ltd. |
| 18556728 | AQUEOUS DISPERSION | Final Rejection | DIC Corporation |
| 17909693 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | Final Rejection | SYMRISE AG |
| 17803774 | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
| 18452342 | EMULSION COMPONENT AND OIL-IN-WATER SUNSCREEN PRODUCT AND OIL-IN-WATER SUNSCREEN LOTION INCLUDING THE SAME | Final Rejection | PATECH FINE CHEMICALS CO., LTD. |
| 17906797 | MINERAL SUNSCREEN COMPOSITION | Non-Final OA | Edgewell Personal Care Brands, LLC |
| 18684452 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | Non-Final OA | Topas Therapeutics GmbH |
| 17904311 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | Final Rejection | TOPAS THERAPEUTICS GMBH |
| 18003303 | COMPOUNDS AS SELF-TANNING SUBSTANCES AND TANNING COMPOSITIONS THEREOF | Final Rejection | ChemoSensoryX Biosciences SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy